Stock Taper 
InflaRx N.V., a German and U.S.-based biopharma, develops C5a inhibitors like vilobelimab for autoimmune and inflammatory diseases, with multiple products in clinical trials.
Gohibic, a first-in-class monoclonal antibody by InflaRx, inhibits C5a to reduce inflammation and is authorized in the EU and EUA in the U.S. for treating critically ill COVID-19 ARDS patients.
InflaRx announced positive topline data from its Phase 2a clinical trial for INF904, an oral C5aR inhibitor, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The news was a major catalyst for the company, coming just months after a different drug's Phase 3 trial was stopped for futility, and it sparked a significant rally in the company's stock price.
InflaRx N.V. initiated a significant corporate restructuring to focus its resources on the development of its lead drug candidate, izicopan, for hidradenitis suppurativa (HS) and other inflammatory and immunology indications. This strategic shift includes a workforce reduction of approximately 30% and a substantial decrease in spending on its FDA-authorized COVID-19 treatment, Gohibic (vilobelimab), to extend the company's cash runway.
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 STTK | $5.77 | COMPARE |
 ARTV | $6.78 | COMPARE |
 STRO | $16.08 | COMPARE |
 CNTB | $0.91 | COMPARE |
 KLRS | $2.50 | COMPARE |
 IMA | $4.12 | COMPARE |
 MGX | $0.99 | COMPARE |
 CNTX | $0.31 | COMPARE |
